AttorneyMind Disease Progression

AbbVie Presents New Phase 2 Data for Investigational, Once-Daily, Ribavirin-Free, Pan-Genotypic Regimen of ABT-493 and ABT-530 for Hepatitis C Genotypes 1-6 April 18, 2016
Merck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress April 18, 2016
Study shows generics pose safe, economic option for patients with April 16, 2016
Hepatitis C: no more treatment rationing; universal access to generic medicines everywhere! April 16, 2016